4-(1,2,4-triazol-1-yl)butyric acid benzyl ester | 158147-50-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1,2,4-triazol-1-yl)butyric acid benzyl ester
• 英文别名: benzyl 4-(1,2,4-triazol-1-yl)butyrate；benzyl 4-(1,2,4-triazol-1-yl)butanoate
• CAS: 158147-50-3
• 化学式: C₁₃H₁₅N₃O₂
• 分子量: 245.281
• InChiKey: VTHJBWNRMDSTDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1,2,4-triazol-1-yl)butyric acid benzyl ester 在 palladium on activated charcoal 氢气 、 N,N'-羰基二咪唑 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 21.0h， 生成 6-(1,2,4-triazol-1-yl)-3-oxohexanoic acid ethyl ester
  参考文献：
  名称：

  Studies on Disease-Modifying Antirheumatic Drugs:  Synthesis of Novel Quinoline and Quinazoline Derivatives and Their Anti-inflammatory Effect

  摘要：

  In the course of our study aimed at developing new types of DMARDs (disease-modifying antirheumatic drugs), we found that quinoline derivative 1a had a potent anti-inflammatory effect in an adjuvant arthritis (AA) rat model, starting from the potent bone resorption inhibitors justicidins as the lead compounds. Further modification of la was performed, and various quinoline and quinazoline derivatives having a heteroaryl moiety on the alkyl side chain at the 2-position of the skeleton were prepared. These compounds were evaluated for antiinflammatory effects using the AA rat model. Most of these compounds, especially those having an imidazole or a triazole moiety on the 2-alkyl chain, exhibited a potent effect. Among the compounds synthesized, ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-yl-methyl)quinoline-3-carboxylate (12d), having an ED(50) value of 2.6 mg/kg/day (anti-inflammatory effect in an AA rat model, po), was selected as a candidate for further investigation. In vitro, 12d inhibited mitogen-induced proliferation at 10(-7)-10(-5) M but not prostaglandin E(2) production at 10(-5) M. Moreover, 12d preferentially inhibited the IFN-gamma production by Th1-type clones over the IL-4 production by Th2-type clones. This preferential suppression of Th1 cytokine production is considered the essential immunomodulating action of 12d for the present. Synthesis and structure-activity relationships for this novel series of quinoline and quinazoline derivatives are detailed.

  DOI：

  10.1021/jm9509408
• 作为产物：
  描述：

  1H-1,2,4-三唑 、 4-溴丁酸苄酯 在 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 4-(1,2,4-triazol-1-yl)butyric acid benzyl ester
  参考文献：
  名称：

  Peripheral vasodilating agent containing piperidine derivative as active

  摘要：

  本发明涉及一种新型外周扩血管药物，其特征在于每种药物均包含作为活性成分的哌啶衍生物或其具有优异外周扩血管活性的药用盐。所述的哌啶衍生物或其药用盐由通式（1）表示：##STR1##（其中R、R.sup.1和R.sup.2与上文中定义的相同）。

  公开号：

  US05656642A1

文献信息

• Peripheral vasodilating agent containing piperidine derivative as active
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05656642A1

  公开（公告）日：1997-08-12

  The present invention relates to novel peripheral vasodilating agents characterized by each containing as an active ingredient, a piperidine derivative or pharmaceutically acceptable salt thereof having excellent peripheral vasodilating activity. Said piperidine derivative or pharmaceutically acceptable salt thereof is represented by the general formula (1): ##STR1## (wherein R, R.sup.1 and R.sup.2 are the same as defined above.

  本发明涉及一种新型外周扩血管药物，其特征在于每种药物均包含作为活性成分的哌啶衍生物或其具有优异外周扩血管活性的药用盐。所述的哌啶衍生物或其药用盐由通式（1）表示：##STR1##（其中R、R.sup.1和R.sup.2与上文中定义的相同）。
• Pharmaceutical composition containing quinoline or quinazoline
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05719157A1

  公开（公告）日：1998-02-17

  The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient.

  本发明提供了一种用于抑制骨吸收或预防/治疗骨质疏松症的药物组合物，其包含喹啉或喹啉衍生物作为活性成分。
• [EN] PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS<br/>[FR] AGENTS VASODILATATEURS PERIPHERIQUES COMPORTANT COMME PRINCIPE ACTIF DES DERIVES DE LA PIPERIDINE 4-AMINO N-ACYLEE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：WO1994022826A1

  公开（公告）日：1994-10-13

  (EN) The present invention relates to novel peripheral vasodilating agents characterized by each containing as an active ingredient, a piperidine derivative or pharmaceutically acceptable salt thereof having excellent peripheral vasodilating activity. Said piperidine derivative or pharmaceutically acceptable salt thereof is represented by general formula (1), wherein R, R1 and R2 are the same as defined above.(FR) Nouveaux agents dilatateurs périphériques contenant individuellement comme principe actif un dérivé de la pipéridine ou l'un de ses sels pharmaco-compatibles et présentant une excellente activité vasodilatatrice périphérique. Lesdits dérivés de la pipéridine ou leurs sels pharmaco-compatibles sont représentés par la formule générale (1) où R, R1 et R2 sont conformes à la définition ci-dessus.

  (EN) 本发明涉及一种新型周围血管扩张剂，其特征在于每种扩张剂均包含作为活性成分的哌啶衍生物或其药学上可接受的盐，具有出色的周围血管扩张活性。所述哌啶衍生物或其药学上可接受的盐由通式（1）表示，其中R，R1和R2与上述定义相同。 (FR) La présente invention concerne de nouveaux agents vasodilatateurs périphériques caractérisés chacun par la présence, en tant que principe actif, d'un dérivé de pipéridine ou de l'un de ses sels pharmaceutiquement acceptables présentant une excellente activité vasodilatatrice périphérique. Lesdits dérivés de pipéridine ou leurs sels pharmaceutiquement acceptables sont représentés par la formule générale (1), dans laquelle R, R1 et R2 sont tels que définis ci-dessus.
• Pharmaceutical composition containing quinoline or quinazoline derivatives
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0634169A1

  公开（公告）日：1995-01-18

  The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient.

  本发明提供了一种用于抑制骨吸收或预防或治疗骨质疏松症的药物组合物，其活性成分包括喹啉或喹唑啉衍生物。
• CHROMATOGRAPHIC COLUMNS AND SEPARATION DEVICES COMPRISING A SUPERFICIALLY POROUS MATERIAL; AND USE THEREOF FOR SUPERCRITICAL FLUID CHROMATOGRAPHY AND OTHER CHROMATOGRAPHY
  申请人：Waters Technologies Corporation

  公开号：EP3936226A2

  公开（公告）日：2022-01-12

  The present invention provides novel chromatographic materials, e.g., for chromatographic separations, processes for its preparation and separations devices containing the chromatographic material; separations devices, chromatographic columns and kits comprising the same; and methods for the preparation thereof. The chromatographic materials of the invention are superficially porous chromatographic particulate materials comprising sized less than 2 microns.

  本发明提供了新型色谱材料，例如用于色谱分离的色谱材料、其制备工艺和含有该色谱材料的分离装置；包含该色谱材料的分离装置、色谱柱和试剂盒；以及其制备方法。本发明的色谱材料是表面多孔的色谱颗粒材料，其尺寸小于 2 微米。